# A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

> **NCT05574010** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA** · enrollment: 128 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Cohort 1 in Part A
- **DRUG:** Cohort 2 in Part A
- **OTHER:** Placebo: Group 1 in Part B and Part C
- **DRUG:** Group 2 in Part B and Part C
- **DRUG:** Group 3 in Part B and Part C
- **DRUG:** Group 4 in Part B and Part C

## Key facts

- **NCT ID:** NCT05574010
- **Lead sponsor:** Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-11-29
- **Final completion:** 2025-05-19
- **Target enrollment:** 128 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05574010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05574010, "A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05574010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*